You are here: Industry Insights > HemaCare

News List

Charles River Laboratories wraps up $380m acquisition of HemaCare pharmaceutical-business-review
January 09, 2020
Charles River Laboratories International has wrapped up its $380m acquisition of HemaCare, a California-based human-derived cellular products provider for the cell therapy market.
Charles River Laboratories to buy HemaCare for $380m pharmaceutical-business-review
December 20, 2019
Charles River Laboratories International has agreed to acquire human-derived cellular products provider HemaCare for around $380m in cash.
Charles River Laboratories to acquire HemaCare for $380m pharmaceutical-technology
December 18, 2019
Charles River Laboratories International has signed a definitive agreement to acquire cellular products developer HemaCare for a cash consideration of approximately $380m.
HemaCare provides human derived biological material to China biospectrumasia
August 28, 2019
New distribution partnership allows high-quality human primary cells to reach the Chinese market